PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT				
NATURE OF CONVEYANCE:			ASSIGNMENT		
CONVEYING PARTY I	DATA				
N			Name	Execution Date	
Naamit SHER				04/17/2013	
Victor M. YOUNG				05/03/2013	
Alyn MCNAUGHTON		05/03/2013			
Massoud BAKHSHAE	E			05/03/2013	
lan Robert WILDING				04/17/2013	
RECEIVING PARTY DATA					
Name:	Vascular Biogenics Ltd.				
Street Address:	6 Jonathan Netanyahu Street				
City:	Or Yehuda				
State/Country:	ISRAEL				
Postal Code:	60376				
PROPERTY NUMBER	S Total: 2			er	
Property Type			Number		
Application Number: 13792		13792	2633 12053533		
		12053533			
CORRESPONDENCE DATA					
Fax Number:2023712540Correspondence will be sert via US Mail when the fax attempt is unsuccessful.Phone:202-371-2600Email:usplittgerber@skgf.com, Imiller@skgf.comCorrespondent Name:Sterne, Kessler, Goldstein & Fox PLLCAddress Line 1:1100 New York Avenue, NWAddress Line 4:Washington, DISTRICT OF COLUMBIA 20005					
ATTORNEY DOCKET NUMBER:		3182.0130002/GLL/CMB/U-S			
NAME OF SUBMITTER:		Ute Splittgerber			
502346510			1	REEL: 030411 FRAME: 0474	

Signature:	/Ute Splittgerber #60,347/		
Date:	05/14/2013		
Total Attachments: 6 source=3182.0130002 and 013PC01 assignment#page1.tif source=3182.0130002 and 013PC01 assignment#page2.tif source=3182.0130002 and 013PC01 assignment#page3.tif source=3182.0130002 and 013PC01 assignment#page4.tif source=3182.0130002 and 013PC01 assignment#page5.tif source=3182.0130002 and 013PC01 assignment#page6.tif			

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Naamit SHER, (2) Victor M. YOUNG, (3) Alya MCNAUGHTON, (4) Massoud BAKHSHAEE and (5) Ian Robert WILDING, hereby sell and assign to Vascular Biogenics Ltd., a corporation formed under the laws of Israel, whose mailing address is 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as Formulations and Dosage Forms of Oxidized Phospholipids for which application(s) for patent in the United States of America has an International filing date of August 31, 2012 (also known as International Application No. PCT/US2012/053533), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-inpart), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

Appl. No. PCT/US2012/053533 Atty. Docket No. 3182.013PC01/GLL/CMB/U-S

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>17, 4, 13</u>	Signature of Inventor: [(1) Naamit SHER
Date:	Signature of Inventor:	(2) Victor M. YOUNG
Date:	Signature of Inventor:	(3) Alyn MCNAUGHTON
Date:	Signature of Inventor:	(4) Massoud BAKHSHAEE
Date:	Signature of Inventor:	(5) Ian Robert WILDING

1672978_1.DOCX

Page 2 of 2

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Naamit SHER, (2) Victor M. YOUNG, (3) Alya MCNAUGHTON, (4) Massoud BAKHSHAEE and (5) Ian Robert WILDING, hereby sell and assign to Vascular Biogenics Ltd., a corporation formed under the laws of Israel, whose mailing address is 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as Formulations and Desage Forms of Oxidized Phospholipids for which application(s) for patent in the United States of America has an International filing date of August 31, 2012 (also known as International Application No. PCT/US2012/053533), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-inpart), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

> PATENT REEL: 030411 FRAME: 0478

Appl. No. PCT/US2012/053533 Atty. Docket No. 3182.013PC01/GLL/CMB/U-S

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

_ Signature of Inventor: _	
	(1) Naamit SHER
Signature of Inventor:	V.M. Your
	(2) Victor M./OUNG
	Ma
	(3) Alyn MCNAUGHTON
	-In-brannin
	(4) Massoud BAKHSHAEE
Signature of Inventor:	
	(5) Ian Robert WILDING
	Signature of Inventor: Signature of Inventor: Signature of Inventor:

1672978_1.DOCX

Page 2 of 2

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Naamit SHER, (2) Victor M. YOUNG, (3) Alyn MCNAUGHTON, (4) Massoud BAKHSHAEE and (5) Ian Robert WILDING, hereby sell and assign to Vascular Biogenics Ltd., a corporation formed under the laws of Israel, whose mailing address is 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as Formulations and Dosage Forms of Oxidized Phospholipids for which application(s) for patent in the United States of America has an International filing date of August 31, 2012 (also known as International Application No. PCT/US2012/053533), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-inpart), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

Appl. No. PCT/US2012/053533 Atty. Dockst No. 3182.013PC01/GLL/CMB/U-S

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with CUSTOMER NUMBER 26111 are the legal representatives of, and attorneys for, the assignee, and are <u>NOT</u> the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Signature of Inventor:	
	(1) Naamit SHER
Signature of Inventor:	
	(2) Victor M. YOUNG
Signature of Inventor:	
	(3) Alyn MCNAUGHTON
Signature of Inventor:	
	(4) Massoud BAKHSHAEE
Signature of Inventor:	I- wortchings
~ `	(5) Ian Robert WILDING
	-

1672978_1.DOCX

Page 2 of 2

RECORDED: 05/14/2013